What's really in women's compounds? Community Testing System Bulletin
January – June 2026 · IPED Trends Series
For women who want to avoid masculinising effects, getting the right compound at the right dose matters, but compounds preferred by women are often misrepresented on the illicit market. This bulletin looks at 243 samples labelled as methenolone enanthate, oxandrolone, drostanolone propionate, stanozolol or clenbuterol, drawn from the 612 samples tested by consumers with PEDTest reagent kits between January and June 2026. Samples were selected by the product declared, so they are relevant to women's use rather than confirmed to come from women. Reagent tests indicate the likely presence of a compound, not its purity or dose.
Key Findings
Key Takeaways
- Fewer than one in three (30.9%; 75 of 243) samples relevant to women’s use matched their label, and half (51.0%) were swapped for another compound.
- Only 1 in 9 Primo E (methenolone enanthate) vials was confirmed as labelled. In 43 samples it contained Mast E instead, 81.1% of all identified substitutions.
- Anavar (oxandrolone), often marketed as lower risk for women, matched its label in just over half of samples (57.8%). Six contained Dianabol, and none of the four Winstrol samples were confirmed.
Recommended Citation
Akrigg K., Bonenti B., Higl L., Oei J., Ferris J., Craven A., Davey G., Kill E., Weith S., Piatkowski T. (2026). ROIDTrends Community Testing System: Testing outcomes for selected IPEDs relevant to women’s use, January–June 2026. Brisbane, Australia: The University of Queensland. https://doi.org/10.14264/eb4ea36
Funding
ROIDTrends is funded by the Queensland Mental Health Commission.
Copyright
This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager.